Wellness Center USA announces development of Neurotherapy Devices Group

157

Wellness Center USA has announced the creation of a group of neuropsychologists, physiologists and medical device engineers to design and develop a set of neurotherapy devices and related software applications (apps).

These devices and apps are intended for use in both home and in-office settings to address brain-based behavioral health disorders without the use of drugs. Wellness Center USA’s two wholly owned subsidiaries CNS-Wellness (CNS) and Psoria-Shield (PSI), will spearhead the joint development of the technology tool set. The first device to be developed is tentatively named the CNS-1000, which will combine CNS’s cognitive neuroscience therapy modalities with PSI’s medical device development and manufacturing expertise.

CNS’s therapies range from reducing chronic pain, to affective (emotional) and stress-related problems such as anxiety, depression and related mood disorders, developmental disabilities and conditions, including autistic spectrum disorders, as well as dis-regulatory conditions such as AD/HD and epilepsy.


PSI, the device development and manufacturing arm of this endeavor, is a leader in medical device design, development and manufacturing. PSI’s team has developed over 40 FDA and CE mark cleared medical devices sold worldwide, ranging from electronics and mechanical design to custom software and regulatory support.


“Expansion of our clinic is at the core of our business model. However, development of the tool set of in-office and home-use devices, according to highest quality design and manufacturing standards, has been within the scope of our plans for several years. Through Wellness Center USA, we now have the design and manufacturing expertise of Psoria-Shield to realise the potential device market sooner than anticipated. Our interventional modalities are proven, and in many cases result in permanent relief. Integration of these methods into a device tool set that allows further improvements in patient access will improve the quality of life for millions and reduce cost centres in our medical system,” said William A Lambos, chief cognitive neuroscientist of CNS and a licensed psychologist.

 

(Visited 11 times, 1 visits today)